Canagliflozin/metformin

Canagliflozin/metformin Reactions 1680, p78 - 2 Dec 2017 Euglycaemic diabetic ketoacidosis and severe hypophosphataemia: case report A 32-year-old woman developed euglycaemic diabetic ketoacidosis (DKA) and severe hypophosphataemia during treatment with canagliflozin/metformin [route and dosage not stated]. The woman, who had a history of type 2 diabetes, presented to the emergency department with a 1 week history of nausea and intractable emesis. Two months prior to the presentation, she had started receiving a combination therapy with canagliflozin/metformin for type 2 diabetes. On admission, her laboratory test results revealed blood glucose level of 277 mg/dL, anion gap of 19 mmol/L, bicarbonate level of 8 mmol/L, serum pH of 7.22, creatinine level of 0.81 mg/dL, potassium level of 4.4 mEq/L, corrected serum sodium level of 129 mmol/L with a positive serum and urine ketone levels. She was diagnosed with euglycaemic DKA. The woman was treated with sodium chloride [normal saline] and insulin. At a blood glucose level of 200 mg/dL, the fluids were switched to glucose [dextrose] and sodium chloride. At that time, her serum phosphate level was <1 mg/dL. However, she was asymptomatic. The phosphate was replaced with potassium phosphate in sodium chloride. Few hours following the treatment, her basic metabolic profile (BMP) revealed a sodium level of 134 mmol/L, potassium level of 3.3 mmol/L, bicarbonate level of 11 mmol/L, anion gap of 11 mmol/L and phosphate level of 1.6 mg/dL. She was treated with potassium, sodium and phosphate. Subsequently, her symptoms improved. Subsequent BMP and arterial blood gas measurements were normal. At this point, her insulin therapy and IV fluids were stopped. She started to tolerate the food with an improvement in her appetite. She was eventually discharged on insulin lispro. Author comment: "Herein, we describe the case of a patient with type 2 diabetes who presented with euglycemic DKA within 2 months of starting canagliflozin/metformin therapy" "Therefore, we speculate that the antecedent use of canagliflozin may have contributed to severe hypophosphatemia during her recovery from DKA." Shoukat S, et al. Euglycemic diabetic ketoacidosis accompanied by severe hypophosphatemia during recovery in a patient with type 2 diabetes being treated with canagliflozin/ metformin combination therapy. Clinical Diabetes 35: 249-251, No. 4, Oct 2017. Available from: URL: http://doi.org/10.2337/cd16-0027 - USA 803285038 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Canagliflozin/metformin

Reactions Weekly , Volume 1680 (1) – Dec 2, 2017
Free
1 page

Loading next page...
1 Page
 
/lp/springer_journal/canagliflozin-metformin-H8QRrQslIp
Publisher
Springer Journals
Copyright
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-017-39009-y
Publisher site
See Article on Publisher Site

Abstract

Reactions 1680, p78 - 2 Dec 2017 Euglycaemic diabetic ketoacidosis and severe hypophosphataemia: case report A 32-year-old woman developed euglycaemic diabetic ketoacidosis (DKA) and severe hypophosphataemia during treatment with canagliflozin/metformin [route and dosage not stated]. The woman, who had a history of type 2 diabetes, presented to the emergency department with a 1 week history of nausea and intractable emesis. Two months prior to the presentation, she had started receiving a combination therapy with canagliflozin/metformin for type 2 diabetes. On admission, her laboratory test results revealed blood glucose level of 277 mg/dL, anion gap of 19 mmol/L, bicarbonate level of 8 mmol/L, serum pH of 7.22, creatinine level of 0.81 mg/dL, potassium level of 4.4 mEq/L, corrected serum sodium level of 129 mmol/L with a positive serum and urine ketone levels. She was diagnosed with euglycaemic DKA. The woman was treated with sodium chloride [normal saline] and insulin. At a blood glucose level of 200 mg/dL, the fluids were switched to glucose [dextrose] and sodium chloride. At that time, her serum phosphate level was <1 mg/dL. However, she was asymptomatic. The phosphate was replaced with potassium phosphate in sodium chloride. Few hours following the treatment, her basic metabolic profile (BMP) revealed a sodium level of 134 mmol/L, potassium level of 3.3 mmol/L, bicarbonate level of 11 mmol/L, anion gap of 11 mmol/L and phosphate level of 1.6 mg/dL. She was treated with potassium, sodium and phosphate. Subsequently, her symptoms improved. Subsequent BMP and arterial blood gas measurements were normal. At this point, her insulin therapy and IV fluids were stopped. She started to tolerate the food with an improvement in her appetite. She was eventually discharged on insulin lispro. Author comment: "Herein, we describe the case of a patient with type 2 diabetes who presented with euglycemic DKA within 2 months of starting canagliflozin/metformin therapy" "Therefore, we speculate that the antecedent use of canagliflozin may have contributed to severe hypophosphatemia during her recovery from DKA." Shoukat S, et al. Euglycemic diabetic ketoacidosis accompanied by severe hypophosphatemia during recovery in a patient with type 2 diabetes being treated with canagliflozin/ metformin combination therapy. Clinical Diabetes 35: 249-251, No. 4, Oct 2017. Available from: URL: http://doi.org/10.2337/cd16-0027 - USA 803285038 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680

Journal

Reactions WeeklySpringer Journals

Published: Dec 2, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off